Fatty liver and diabetes share insulin resistance as a common root cause, creating a harmful cycle that millions of Indian patients face silently. Early awareness, ... Jun 18
Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline ... Apr 04
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ... Oct 16
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ... Oct 15
A study published in a major medical journal revealed that individuals with type 2 diabetes who were treated with SGLT-2 inhibitors had a lower ... Aug 30
Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of ... Oct 19
-Advertisements-